Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

Clinical Evaluation of the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis -BIOPRO TRIAL

Collect data on the safety and clinical performance of the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

Study Overview

• Status: Recruiting
• Conditions: Aortic Valve Stenosis; Mitral Valve Insufficiency; Aortic Valve Insufficiency; Mitral Valve Stenosis; Mitral Valve Regurgitation; Aortic Valve Incompetence; Mitral Valve Incompetence; Aortic Valve Regurgitation
• Intervention / Treatment: Device: Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis.

Detailed Description

Multicenter, observational, retrospective, non-comparative, non-randomized study to determine the safety and clinical performance of the Bovine Pericardium Valvular Bioprosthesis in patients who required replacement of their native or bioprosthetic valve (aortic or mitral), according to ISO 14155 and ISO 5840.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Glaucia Basso; Phone Number: +55 (17) 2136-7005; Email: glaucia.basso@braile.com.br

Study Locations

• Brazil
  • São Paulo, Brazil
    • Not yet recruiting
    • INCOR - Instituto do Coração do Hospital das Clínicas da FMUSP
    • Principal Investigator: Pablo Pomerantzeff
  • Bahia
    • Salvador, Bahia, Brazil
      • Recruiting
      • Hospital Ana Nery - HAN/SESAB
      • Principal Investigator: Luiz Carlos Passos
  • RS
    • Porto Alegre, RS, Brazil
      • Recruiting
      • Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA
      • Principal Investigator: Fernando Lucchese

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing valve replacement (aortic or mitral) with Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis, from 2013 to 2021.

Description

Inclusion Criteria:

(Group I - Aortic):

• Symptomatic patients with severe aortic insufficiency.
• Asymptomatic patients with severe aortic insufficiency and left ventricular ejection fraction (LVEF) at rest ≤ 50%.
• Patients with severe aortic insufficiency and undergoing coronary artery bypass graft surgery (CABG) or surgery of the ascending aorta or other valve.
• Asymptomatic patients with severe aortic insufficiency and resting ejection fraction > 50% with severe left ventricular (LV) dilation: left ventricular end-diastolic diameter (LVDD) > 70 mm or left ventricular ejection fraction (LVEF) > 50 mm (or LVEF > 25 mm/m2 of body surface, in patients with small body size).
• Symptomatic patients with severe high gradient aortic stenosis (mean gradient ≥ 40 mmHg or peak velocity ≥ 4.0 m/s).
• Symptomatic patients with severe low-flow, low-gradient aortic stenosis (< 40 mmHg) with reduced ejection fraction and evidence of flow reserve (contractile) excluding pseudo-severe aortic stenosis.
• Symptomatic patients with low-flow, low-gradient (< 40 mmHg) aortic stenosis with normal ejection fraction after careful confirmation of severe aortic stenosis.
• Symptomatic patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction without flow reserve (contractile), particularly when the amount of calcium on computed tomography (CT) confirms severe aortic stenosis.
• Patients with symptomatic aortic stenosis at low surgical risk (STS or EuroSCORE II < 4% or logistic EuroSCORE I < 10% and no other risk factors not included in these scores, such as fragility, porcelain aorta, sequelae of thoracic radiation).
• Asymptomatic patients with severe aortic stenosis and LV systolic dysfunction (LVEF < 50%) not due to another cause.
• Asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing exercise symptoms clearly related to aortic stenosis.
• Asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing a decrease in blood pressure below baseline.
• Asymptomatic patients with normal ejection fraction and no exercise stress test abnormality, if the surgical risk is low and have very severe aortic stenosis defined by a peak transvalvular velocity (Vmax) > 5.5 m/s.
• Asymptomatic patients with normal ejection fraction and no exercise test abnormality, if the surgical risk is low and severe valve calcification and Vmax progression rate ≥ 0.3 m/s/year.
• Asymptomatic patients with normal ejection fraction and no exercise stress test abnormality, if surgical risk is low and B-type natriuretic peptide (BNP) marker levels are high.
• Asymptomatic patients with normal ejection fraction and no change in the exercise test, if the surgical risk is low and severe pulmonary hypertension (pulmonary artery systolic arterial pressure at rest > 60 mmHg confirmed by invasive measurement) with no other explanation.
• Patients with severe aortic stenosis undergoing CABG or surgery of the ascending aorta or other valve.
• Patients with moderate aortic stenosis undergoing CABG or surgery of the ascending aorta or other valve after decision by the Heart Team.

7.2. Inclusion Criteria (Group II - Mitral):

• Symptomatic patients with severe primary mitral insufficiency and LVEF > 30%.
• Asymptomatic patients with severe primary mitral insufficiency and LV dysfunction (LVEF > 45 mm and/or LVEF < 60%).
• Asymptomatic patients with severe primary mitral regurgitation and preserved LV function (LVEF < 45 mm and LVEF > 60%) and atrial fibrillation secondary to mitral regurgitation or pulmonary hypertension (rest systolic pulmonary pressure > 50 mmHg).
• Asymptomatic patients with severe primary mitral regurgitation and preserved LVEF (> 60%) and LVEF 40-44 mm, with leaflet failure.
• Asymptomatic patients with severe primary mitral regurgitation and preserved LVEF (> 60%) and LVEF 40-44 mm, and presence of significant LA dilation (volume index ≥ 60 mL/m2 of body surface) in sinus rhythm.
• Patients with severe primary mitral regurgitation and severe LV dysfunction (LVEF < 30% and/or LVEF > 55 mm) refractory to medical therapy.
• Patients with severe chronic secondary mitral regurgitation undergoing CABG and LVEF > 30%.
• Symptomatic patients with severe secondary mitral regurgitation, LVEF < 30%, but with the option of revascularization and evidence of myocardial viability.
• Patients with severe secondary mitral regurgitation and LVEF > 30% who remain symptomatic despite optimal clinical treatment and with low surgical risk.
• Symptomatic patients with mitral stenosis (valve area ≤ 1.5 cm2) who are not suitable for percutaneous mitral commissurotomy.

Exclusion Criteria:

• Emergency surgical valve replacement.
• Surgical replacement of the aortic root.
• Patients who did not return for follow-up examinations.
• Patients with renal impairment as determined by creatinine level ≥ 2.5 mg/dL or end-stage renal disease requiring chronic dialysis.
• Patients with stroke or transient ischemic attack within 6 months (180 days) before planned valve surgery.
• Patients with acute myocardial infarction within 30 days before planned valve surgery.
• Patients with any known life-threatening non-cardiac disease that will limit the patient's life expectancy below 1 year.
• Patients diagnosed with abnormal calcium metabolism and hyperparathyroidism.
• LVEF ≤ 20%, as validated by the diagnostic procedure before planned valve surgery.
• Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.
• Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery.
• Documented leukopenia (leukocytes < 3.5x10³/μL), acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L) or thrombocytopenia (platelet count < 50x10³/μL) accompanied by a history of bleeding diathesis and coagulopathy.
• Patients who underwent organ transplantation.
• Pregnant or breastfeeding.
• Patients with a documented history of substance abuse (drugs or alcohol) in the last year before implantation.
• Concomitant positioning of the left ventricular assist device.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical success	Valve implantation without occurrences and without serious adverse events until hospital discharge.	Until discharge from the index hospitalization (an average of 7 days is expected).
Composite event	Defined as death, stroke, and/or reintervention after 1 year of follow-up.	01 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Extracorporeal circulation time AND Aortic clamping time (minutes)		during the procedure
Intensive care unit (ICU) time (days)		Until discharge from the index hospitalization (an average of 2 days is expected)
Length of in-hospital stay (days)		Until discharge from the index hospitalization (an average of 7 days is expected).
New York Heart Association (NYHA) dunctional class at 5 years post-implant compared to baseline	The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.	at discharge, 30 days, 6 months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Valve related adverse events	structural valve deterioration, non-structural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death	at discharge, 30 days, 6 months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Early rates AND late linearized rates AND actuarial rates of valve-related adverse events	thromboembolism, valve thrombosis, all bleeds, major bleeds, paravalvular leaks, severe paravalvular leaks, endocarditis, non-structural dysfunction, structural valve deterioration (rupture and calcification)	at discharge, 30 days, 6 months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Subject's average peak systolic gradient (mmHg) measurements at 5 years post-implant		5 years post-implant
Subject's average mean systolic gradient (mmHg) measurements at 5 years post-implant.		5 years post-implant
Subject's average effective orifice area measurements at 5 years post-implant		5 years post-implant
Subject's average effective orifice area index (EOAI) measurements at 5 years post-implant		5 years post-implant
Subject's average performance index measurements at 5 years post-implant		5 years post-implant
Subject's average cardiac output measurements at 5 years post-implant		5 years post-implant
Subject's amount of aortic valvular regurgitation at 5 years post-implant		5 years post-implant

Collaborators and Investigators

• Sponsor: Braile Biomedica Ind. Com. e Repr. Ltda.
• Investigators: Principal Investigator: Fernando Lucchese, Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2023
• Primary Completion (Estimated): July 1, 2023
• Study Completion (Estimated): October 30, 2023

Study Registration Dates

• First Submitted: May 11, 2023
• First Submitted That Met QC Criteria: June 5, 2023
• First Posted (Actual): June 15, 2023

Study Record Updates

• Last Update Posted (Actual): June 15, 2023
• Last Update Submitted That Met QC Criteria: June 5, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Pathological Conditions, Anatomical; Aortic Valve Disease; Heart Valve Diseases; Ventricular Outflow Obstruction; Aortic Valve Stenosis; Mitral Valve Insufficiency; Aortic Valve Insufficiency; Constriction, Pathologic; Mitral Valve Stenosis
• Other Study ID Numbers: BIOPRO Trial

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No